Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 4239-4246

  Zeng, Wen ^a   Meng, Fankai ^a   Liu, Zeming ^a   Mao, Xia ^a   Luo, Li ^a   Zheng, Miao ^a   Qin, Shuang ^a   Liu, Wenli ^a   Zhou, Jianfeng ^a   Sun, Hanying ^a   Huang, Lifang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bcl 2; Bortezomib; Multiple myeloma; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; MELPHALAN; PREDNISONE; PROTEIN BCL 2; PYRAZINE DERIVATIVE; THALIDOMIDE; VINCRISTINE;

AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE; VINCRISTINE;

EID: 84906270606     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Palumbo A and Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
3. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M and Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012; 120: 173-180.
4. Tyner JW, Jemal AM, Thayer M, Druker BJ and Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 2012; 26: 623-632.
5. Bedewy AM, Elgammal MM, Bedewy MM and El-Maghraby SM. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. Ann Hematol 2013; 92: 1359-1367.
6. Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivkovic R, Hajder J, Stanisavljevic N and Mihaljevic B. Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol 2012; 29: 3515-3521.
7. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL and Grossman D. Survivin promotion of melanoma metastasis requires upregulation of alpha5 integrin. Carcinogenesis 2013; 34: 2137-2144.
8. Ye Q, Cai W, Zheng Y, Evers BM and She QB. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014; 33: 1828-1839.
9. Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R and Barille-Nion S. Significant impact of survivin on myeloma cell growth. Leukemia 2007; 21: 1070-1078.
10. Romagnoli M, Seveno C, Wuilleme-Toumi S, Amiot M, Bataille R, Minvielle S and Barille-Nion S. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. Br J Haematol 2009; 145: 180-189.
11. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K and Kitagawa M. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81: 824-831.
12. Tsubaki M, Satou T, Itoh T, Imano M, Komai M, Nishinobo M, Yamashita M, Yanae M, Yamazoe Y and Nishida S. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk Res 2012; 36: 1315-1322.
13. Kaneko N, Mitsuoka K, Amino N, Yamanaka K, Kita A, Mori M, Miyoshi S and Kuromitsu S. Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma. Clin Cancer Res 2014; 20: 1814-1822.
14. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S and Papadopoulos KP. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118: 3128-3134.
15. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A and Waldmann TA. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013; 121: 2029-2037.
16. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C and Amiot M. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118: 3901-3910.
17. Durie BG and Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
18. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I and Westin J. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
19. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J and Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 2009; 7: 908-942.
20. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G and Rajkumar SV. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
21. Liman N, Alan E, Bayram GK and Gurbulak K. Expression of survivin, Bcl-2 and Bax proteins in the domestic cat (Felis catus) endometrium during the oestrus cycle. Reprod Domest Anim 2013; 48: 33-45.
22. Miguel-Garcia A, Orero T, Matutes E, Carbonell F, Miguel-Sosa A, Linares M, Tarin F, Herrera M, Garcia-Talavera J and Carbonell-Ramon F. bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica 1998; 83: 298-304.
23. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H and Einhorn S. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995; 63: 190-192.
24. Durie BG. Cellular and molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am 1992; 6: 463-477.
25. Renner S, Weisz J, Krajewski S, Krajewska M, Reed JC and Lichtenstein A. Expression of BAX in plasma cell dyscrasias. Clinical cancer research 2000; 6: 2371-2380.
26. Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
27. Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K and Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol 2002; 69: 76-89.
28. Puthier D, Pellat-Deceunynck C, Barille S, Robillard N, Rapp MJ, Juge-Morineau N, Harousseau JL, Bataille R and Amiot M. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999; 13: 289-294.
29. Ferrarini M and Ferrero E. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma. Curr Med Chem 2011; 18: 5185-5195.
30. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, Raab MS, Vallet S, Zhou Y, Cartron MA, Hideshima T, Tai YT, Chauhan D, Anderson KC and Podar K. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res 2009; 69: 5082-5090.
31. Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP and Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012; 53: 1174-1182.
32. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ and Fang B. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24: 4993-4999.
33. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Philippe M, Bataille R and Amiot M. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418-5424.
34. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR and Al-Kuraya KS. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008; 68: 3379-3388.
35. Uddin S, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, Bavi P and Al-Kuraya KS. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest 2009; 89: 1115-1127.
36. Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S and Al-Kuraya KS. Bortezomib inhibits proteasomal degradation of IkappaBalpha and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55: 415-424.
37. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG and Anderson KC. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007; 138: 783-791.
38. Guo S, Zhi Y, Yang H, Yu Y, Wang Y, Zhang J, Wang G, Zhang L, Sun B and Zhang Y. Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone. Ann Hematol 2014; 93: 471-477.